Ephs constitute a quarter of all known human receptor tyrosine kinases. They direct key processes during development and repair of the nervous system, blood-vessel formation, insulin secretion, immune-system function, intestinal homeostasis and bone-tissue integrity 1 . They are grouped into two classes, A and B (ref. 2), but domain composition is conserved across the family (Fig. 1a) . The extracellular region comprises an N-terminal ligand-binding domain (LBD), a cysteine-rich region and two fibronectin type III domains (FN1 and FN2). FN2 connects to the transmembrane helix, followed by an intracellular region comprising a juxtamembrane region, a tyrosine kinase domain and a sterile-α motif (SAM) domain often linked to a C-terminal Psd-95, Dlg and ZO1 domain (PDZ)-binding motif. Structures have been determined for examples of all Eph domains in isolation, with the exception of the cysteine-rich region 3, 4 .
Ephs constitute a quarter of all known human receptor tyrosine kinases. They direct key processes during development and repair of the nervous system, blood-vessel formation, insulin secretion, immune-system function, intestinal homeostasis and bone-tissue integrity 1 . They are grouped into two classes, A and B (ref. 2) , but domain composition is conserved across the family (Fig. 1a) . The extracellular region comprises an N-terminal ligand-binding domain (LBD), a cysteine-rich region and two fibronectin type III domains (FN1 and FN2). FN2 connects to the transmembrane helix, followed by an intracellular region comprising a juxtamembrane region, a tyrosine kinase domain and a sterile-α motif (SAM) domain often linked to a C-terminal Psd-95, Dlg and ZO1 domain (PDZ)-binding motif. Structures have been determined for examples of all Eph domains in isolation, with the exception of the cysteine-rich region 3, 4 .
Activation of Eph receptors depends on the presence of their ligands (ephrins) and involves the packing of Ephs into signaling clusters 1, 4 . Ephrins consist of an N-terminal extracellular receptor-binding domain (ephrin RBD) and a C-terminal extension linked to the plasma membrane by a lipid anchor (class A ephrins) or transmembrane helix (class B ephrins). Binding affinities vary for different Eph-ephrin pairs, but in general, binding within classes is favored 5 . Crystal structures for 1:1 complexes of Eph LBDs bound to ephrin RBDs show a hydrophobic ephrin-binding groove on the receptor and provide insight into ligandreceptor specificity, but the structures do not define a mechanism for ligand-dependent signaling 6 . Members of the Eph family of receptor tyrosine kinases appear to require a more complex form of oligomerization to trigger signaling than the ligand-induced dimerization model developed from studies of systems such as the human growth hormone receptor 7 . Insights into Eph receptor clustering upon ephrin binding are as yet limited 4 . The crystal structure of the EphB2 LBD-ephrinB2 RBD complex revealed a second, putative tetramerization interface 6 . However, five subsequent Eph LBD-ephrin RBD complex crystal structures have not shown evidence for a consistent mode of oligomerization [8] [9] [10] [11] . Biophysical and functional analyses have also implicated additional regions of Eph ectodomains in ephrin-mediated signaling 12 . We therefore sought to provide structural insight into a full Eph receptor ectodomain architecture and its interactions. We focus on human EphA2, which is expressed during embryonic development and in adult epithelia 13 , where it regulates cell adhesion 14, 15 . EphA2 also acts as a powerful oncogene in many tumors by promoting vascularization and metastasis [16] [17] [18] [19] .
RESULTS

Structure of EphA2 ectodomain (eEphA2)
To improve crystallization, we expressed eEphA2 (residues Lys27-Asn534) in glycosylation-impaired mammalian cells 20, 21 , trimmed the resultant glycans down to single N-acetylglucosamine moieties and dimethylated the amino groups 22 . We refined the structure (one molecule per asymmetric unit) to a final R work = 24% (R free = 30%) using data to 3.0-Å resolution. Detailed data and refinement statistics are given in Table 1 . A view of the final electron density map is shown in Supplementary Figure 1 . All five domains are well ordered, and the overall linear arrangement results in an elongated molecule (length ~172 Å, width ~22-48 Å , Fig. 1b) . The previously uncharacterized cysteine-rich region shows the topology of a sushi (CCP) domain followed by an epidermal growth factor (EGF)-like domain. Sequence alignment of class A Ephs mapped onto the eEphA2 structure reveals patches of surface conservation on the LBD and sushi domains (Fig. 1c) . Conserved sushi-domain residues contribute to a crystal contact with a parallel neighboring molecule staggered by A r t i c l e s one domain (Fig. 1c) . In total, interfaces between these molecules bury 2,661 Å 2 of surface area and stabilize linear arrays of staggered, parallel Ephs. These crystal contacts for full-length EphA2 ectodomain do not reiterate the 'head-to-head' contacts recently observed for crystals of EphA2 LBD 10 . Two putative N-linked glycosylation sites, located in the FN1 domain and in the linker between domains FN1 and FN2, are not involved in crystal contacts.
Structure of eEphA2 in complex with ephrinA5 RBD
To compare unliganded eEphA2 with a ligand-bound form, we attempted to crystallize it with a panel of ephrinA ligands and succeeded in producing diffracting crystals of eEphA2 in complex with human ephrinA5 RBD. Dimethylation of the surface-exposed lysine residues and extensive optimization yielded a crystal (containing one eEphA2-ephrinA5 RBD complex per asymmetric unit) from which we collected diffraction data to 4.8-Å resolution. We refined the resultant complex structure by rigid body and translation, libration, screw to R work = 31%, R free = 31% (Fig. 1d) . Crystallographic details are summarized in Table 1 , and an example of the final electron density map is shown in Supplementary Figure 1 . The structure of ephrinA5 RBD in the complex shows no evidence of major structural changes when compared to the previously reported structure 23 of unliganded ephrinA5 RBD. Superposition of ligand-bound and unbound eEphA2s reveals domain reorientations (Supplementary Fig. 2 ). The largest reorientation, a relative rotation of 71° by FN2, shows the hinge-like character of the FN1-FN2 linker. Other points of flexion are located between the LBD and sushi domains and within the EGF-like domain.
The crystal consists of parallel and antiparallel arrays of eEphA2-ephrinA5 RBD complexes (Supplementary Fig. 3 ) formed by interfaces A-F ( Supplementary Fig. 4 and Supplementary Table 1). Interfaces A-E mediate parallel arrays (Figs. 1e and 2a) , whereas interface F stabilizes antiparallel packing (Fig. 2b) . The previously reported Eph LBD-ephrin RBD interaction 3 forms interface A and broadly matches that previously reported for the complex of EphA2 LBD with ephrinA1 RBD 10 (Fig. 2a,c) . Interface C is a small contact between eEphA2 and a second ephrinA5 RBD (Fig. 2a,c) . Interfaces B, D and E connect neighboring eEphA2 molecules via their LBDs, sushi domains and FN1 domains, respectively (Fig. 2a,c-e) . Interfaces B and D use the conserved surface patches, which form the staggered LBD-sushi contact in the unliganded eEphA2 crystals, but in the presence of ephrinA5 RBD, these patches mediate in-register LBD-LBD (interface B) and sushi-sushi (interface D) interactions (Fig. 1e) . Finally, the FN1-FN2 domains from eEphA2 form interface F with ephrinA5 RBD bound (via interface A) to an antiparallel eEphA2 neighbor (Fig. 2b,f) .
EphA2 localization at cell-cell contacts
Recent work has shown that EphA2 localizes at the cell-cell contacts in the mouse eye lens, where it binds to ephrinA5 and maintains tight cellular packing 24 . EphA2 is also known to localize at cell-cell A r t i c l e s contacts when transfected into a range of epithelial cell lines [25] [26] [27] , and we therefore chose to exploit this system to dissect the interaction characteristics of EphA2 in vivo using a human embryonic kidney epithelial cell line (HEK 293T) and fluorescent protein (mVenus)-tagged constructs (Fig. 3) . A series of deletion constructs all showed cell-surface expression (Supplementary Fig. 5 ).
As anticipated, full-length EphA2 accumulated at the contact region between transfected cells (Supplementary Video 1). We did not observe EphA2 accumulation in regions of the cell surface not involved in contacts, or in contact regions between EphA2-expressing and nontransfected native cells (Fig. 3a-c) . These observations imply that trans presentation of EphA2 (in other words, from opposing cells) is required for clustering. We found that deleting individual cytoplasmic domains, or the entire intracellular region, did not prevent cell-surface expression and did not affect the pattern of localization at cell-cell contacts ( Supplementary Fig. 6 and Supplementary Video 2). In contrast, although cell-surface localization was still maintained, deletion of the N-terminal four extracellular domains (LBD-FN1) abolished the specific localization at the cell-cell interface, suggesting that the ectodomain is essential ( Supplementary Fig. 6 and Supplementary Video 3).
Mutations in interfaces A, B, D and F affect EphA2 localization
To investigate which of the interfaces in our crystal structures have biological relevance, we produced a panel of EphA2 point mutants designed to disrupt interfaces A-F (Supplementary Table 1) . Interface B and D mutations resulted in homogeneous EphA2 cell-surface distribution, completely abolishing the wild-type localization pattern (Fig. 3d-f , Supplementary Fig. 6 and Supplementary Video 4). These are the major interfaces for the in-register arrays of liganded eEphA2; the same surfaces form the staggered arrays for unliganded eEphA2 and could mediate cis interaction (between Eph receptors on the same cell) in vivo. Previous mutagenesis studies have indicated that interface B residues can contribute to EphA3-ephrinA5 binding affinity 12 , 
A r t i c l e s
although it is not the main ephrin binding site. Mutations in the minor interfaces C and E had no effect on EphA2 localization (Supplementary Fig. 6 ).
Introduction of an N-linked glycosylation site (EphA2 A190N L192S) to disrupt interface A, the well-established ephrin binding site for binding in trans, abolished cell-cell contact localization (Supplementary Fig. 6 ). As HEK 293 cells express class A ephrins endogenously 28 , these results suggest that binding to endogenous ephrins in trans is necessary to drive localization of expressed EphA2 to cell-cell contacts, a conclusion further supported by studies using insect (Sf9) cells (Supplementary Fig. 6c ). Interface F (the second largest interface in the complex crystals) would in vivo be consistent with a cis interaction between ephrinA5 and EphA2 FN1-FN2; mutations at this interface caused an intermediate phenotype where protein is partially delocalized over the entire cell surface ( Supplementary  Fig. 6 ). This is consistent with previous functional studies suggesting that the FN2 domain of EphA3 binds ephrinA5 in cis 29 .
Specific proteolytic cleavage of EphA2 depends on clustering
Previous studies have demonstrated that activation of Eph receptors leads to their internalization and degradation 30 and specific activationdependent proteolytic cleavage has been reported for EphB2 (refs. 31,32) . We performed immunoblot assays which show that EphA2 is proteolytically cleaved in HEK 293 cells. Upon wild-type EphA2 expression, we observed at least three C-terminal tyrosinephosphorylated EphA2 proteolytic fragments, corresponding to ~70, ~75 and ~95 kDa (including the ~28-kDa mVenus tag, Supplementary  Fig. 7 ). For mutants in interfaces A, B and D, the fragments of ~75 kDa and ~95 kDa are absent. For mutants in interface F, only the ~95-kDa fragment is absent. Notably, the cleavage patterns observed for EphA2 wild type and mutants correlate with their cell-surface localization patterns; interface F mutants have less severe impairment of cell-cell contact localization than interface A, B and D mutants ( Supplementary  Figs. 6 and 7) . The correlation of specific cleavage with localization to cell-cell contacts suggests that this process depends on the ability of the receptor to cluster via interfaces A, B, D and F.
DISCUSSION
Previously reported data for Eph function point to a requirement for receptor clustering into extended cell-surface assemblies 4, [33] [34] [35] . However, full-length Eph ectodomains (eEphA2, eEphB2 and eEphB3) show no propensity to form oligomers in solution (as assessed by multiple-angle light scattering, MALS and analytical ultracentrifugation) either alone or in complex with monomeric, soluble ephrins (ephrinA5 RBD, ephrinA2 RBD and ephrinB2 RBD) (Supplementary Fig. 8 and data not shown). These data accord with previous reports that full-length Eph receptors only cluster if the ephrin ligand is presented in a membranebound or oligomeric form 36 . Nevertheless, at very high concentration in crystals, both unliganded and complexed eEphA2 form array-like networks of interfaces which functional experiments show are relevant to the cell-surface signaling. The eEphA2 arrays involve staggered interactions between the LBD and sushi domains. Ephrin binding snaps the Eph arrays into register with LBD-LBD and sushi-sushi interactions involving the same eEphA2 surface patches. While we were completing our analysis, an independently determined crystal structure of unliganded human EphA2 ectodomain (PDB 3FL7) was deposited by the Structural Genomics Consortium. The lattice includes crystal contacts similar to the in-register form we observed, indicating that this mode of Eph-Eph interaction can also occur without ephrin binding. This implies that, in the absence of ligand, transient cis associations between cell-surface Ephs may occur as a dynamic equilibrium between in-register (LBD-LBD, sushi-sushi) and staggered (LDB-sushi) interactions. For such a system, ephrin binding at 'nucleation' points could trigger more widespread recruitment of EphA2 into in-register arrays containing unliganded receptor, thus facilitating, in a cooperative manner, additional ephrin binding (Fig. 4) . Indeed, it has been reported that once an Eph receptor signaling cluster is nucleated by ephrin binding, further Ephs are recruited to the cluster in an ephrin-independent manner 33 . The above steric 'seeding' mechanism provides a model for how relatively low levels of ephrins can trigger the formation of extended assemblies of EphA2. These assemblies may be further stabilized by transmembrane 37 and cytoplasmic 38 region interactions. Our results illustrate a nucleation mechanism for ectodomain-driven array-based signaling, which could be broadly applicable to other cell-surface receptor systems.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Protein Data Bank: The coordinates for eEphA2 (apo) and for the eEphA2-ephrinA5 complex have been deposited with accession codes 2X10 and 2X11, respectively. 
ONLINE METhODS
Vectors and cloning. We cloned all constructs into the AgeI-KpnI site of pHLsec 21 , thereby fusing the insert with a C-terminal polyhistidine tag. The secreted ectodomain of human EphA2 (Uniprot: P29317) includes residues 27-534 (eEphA2); that of ephrinA5 (Uniprot: P52803) includes residues 27-166 (ephrinA5 RBD). EphA2 and ephrinA5 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] correspond to predicted secretion signals in EphA2 and ephrinA5, respectively 40 . For cell-surface expression, we fused the C terminus of transmembrane human EphA2 constructs to the monomeric fluorescent protein mVenus 41 . We produced the following constructs as mVenus fusions: EphA2 27-976 , EphA2 ∆SAM 27-889 , EphA2 ∆KSAM 27-564 and EphA2 ∆e 436-976 . We also fused the C terminus of ephrinA5 to the monomeric transmembrane helix of receptor protein tyrosine phosphatase RPTPµ (ref. 42) (residues 742-769, Uniprot: P28827) followed by the monomeric fluorescent protein mCherry.
Protein crystallization. We provide details of the protein expression, purification, MALS and immunoblotting in Supplementary Methods. We treated eEphA2 with endoglycosidase F1 (refs. 43,44) and lysine-methylated the protein 22 . Crystals diffracting to 3-Å resolution grew at 20 °C from drops 45 Data collection and processing. Table 1 shows data statistics. We flash-froze selenomethionine derivative crystals of eEphA2 after dipping into perfluoropolyether oil PFO-X125/03 (Lancaster). We collected a 3-Å resolution dataset at 100 K at the selenium edge (wavelength = 0.98 Å) at the European Synchrotron Radiation Facility (ESRF) beamline BM14 using the inverse beam option (rotation every 20 images, corresponding to 10°). We processed the data using XDS 46 and MOSFLM 47 . Molecular replacement using models for the LBD of EphA2 (PDB 3C8X), the FN2 domain of EphB4 (PDB 2E7H) and FN2 domain of EphA8 (PDB 1X5L) yielded initial phases that we used to locate selenium sites in PHASER 48 . We performed electron density modification with DM 49 and manual improvement of the protein model in Coot 50 . Cycles of phase calculation plus model building and refinement iteratively led to a satisfactory model. We used a second crystal, which yielded better data at high resolution at the ESRF beamline ID23-EH2 (100 K, wavelength = 0.87 Å), for the final rounds of refinement. eEphA2 carries two predicted N-glycosylation sites, and we modeled N-acetylglucosamine into the electron density found for one site on the FN1 domain. This N-acetyl-glucosamine molecule is in close proximity to, but not in contact with, the FN2 domain of a neighboring eEphA2 chain. There is no electron density for sugar at the second putative N-glycosylation site located in the poorly defined linker region between FN1 and FN2. This region is also not involved in crystal contacts. We used Coot and MOLPROBITY 51 for model validation. Three residues (0.6%) are located in outlier regions of the Ramachandran plot.
We froze the crystal of eEphA2 in complex with ephrinA5 RBD in cryoprotectant containing one part reservoir and one part reservoir supersaturated with LiCl. After brief equilibration in cryoprotectant, we mounted the crystal on a loop, dipped it into perfluoropolyether oil PFO-X125/03 and flash froze it. We collected the best dataset at 100 K on ESRF beamline ID14-EH2 (wavelength = 0.93 Å) and processed data using XDS. We used a model of human EphA2 ligand-binding domain in complex with ephrin A2 receptor binding domain (PDB 3CZU) for molecular replacement in PHASER (RFZ = 11.1, TFZ = 9.6, LLG = 162). We placed the models of individual eEphA2 domains sequentially into the improving density and refined each using rigid-body refinement in PHASER. Initially, we performed molecular replacement using the 3.0-Å resolution eEphA2 model presented here. After deposition of the 2.5-Å resolution eEphA2 model (PBD 3FL7) by the Structural Genomics Consortium, we used this higher-resolution model. We refined the model using PHENIX 52 (Supplementary Methods). Six residues are in outlier regions of the Ramachandran plot as found in the input molecular replacement model downloaded from the Protein Data Bank. The two putative N-glycosylation sites lie outside crystal contact areas.
To calculate the angle between the orientations eEphA2 FN2 adopts in the unliganded and ephrinA5 RBD-bound structures, we first generated two models of liganded eEphA2 superposed onto the FN1 and FN2 domains of unliganded eEphA2. We then used LSQKAB within the CCP4 suite 53 to calculate the rotation applied to superpose the two resulting structures via their FN2 domain. We produced figures using PyMOL 54 , ESPRIPT 55 , ConSurf 56 and the commercial program packages CorelDRAW (http://www.corel.com) and Adobe (http://www.adobe.com).
Live cell assays. We grew HEK 293T cells in DMEM (Sigma) supplemented with l-glutamine, nonessential residues (Gibco) and 10% (v/v) FCS (Sigma). We transfected the cells with plasmid DNA using lipofectamine 2000 following the recommended protocol (Invitrogen). Final concentrations were 2 µg plasmid DNA per ml, 5 µl lipofectamine per ml and 1.5% (v/v) FCS. After 4-6 h, we replaced the transfection mix with original growth medium, resuspended the cells and plated them on poly-l-lysine-coated glass-bottom culture plates (MatTek). To observe trans interactions of different constructs, we mixed separately transfected cells at this stage. We imaged cells 15-20 h later using a Zeiss LSM510 confocal microscope (with variable emission detectors (MetaHead)). For this time scale, we did not observe cell rounding and death upon EphA2 expression for either HEK 293 or COS7 cells (data not shown). We only compared images taken with the same detector and laser settings; none of the images are enhanced or contrast modified.
